🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT01343342
Active, not recruiting Not applicable

Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors

NCT01343342 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2009-10
Last updated
2026-09-03

Condition(s) studied

Cardiovascular Disease

Investigational drug(s) / intervention(s)

n-3 PUFA supplementation

n-3 PUFA supplementation: 3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)

Study summary

The main purpose of this study is to examine whether n-3 PUFA-induced changes in metabolic risk factors are influenced by genetic variations within genes acting as fatty acids sensors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * healthy men and women aged between 18 to 50 years; * having a BMI between 25 and 40kg/m2; * plasma triglycerides levels \<4.0 mmol/L; * non-smokers; * free of any thyroid or metabolic disorders requiring treatment such as diabetes, hypertension, severe dyslipidemia, and coronary heart disease. Exclusion Criteria: * subjects taking medication for hyperlipidemia, hypertension, diabetes or taking anticoagulant or n-3 PUFA supplementation; * having a taste aversion for fish, fish allergy or regular alcohol drinker; * body mass index \> 40kg/m2; * pregnant or nursing women.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institute of Nutraceutical and Functional Foods (INAF), Laval University Québec Canada

More Laval University trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01343342 on ClinicalTrials.gov ↗ ← All trials in Canada